Lerakta (Lercanidipine Hydrochloride)

Lercanidipine selectively blocks L‑type calcium channels in the smooth muscle of blood vessels. This inhibition prevents calcium‑driven contraction, leading to vasodilation of peripheral arteries, a fall in systemic vascular resistance, and consequently lower arterial pressure.

The dose of Lerakta is individualized by the prescribing clinician based on the patient’s blood‑pressure profile, age, renal and hepatic function, and concomitant therapies. The prescriber determines the appropriate starting dose and any subsequent titration.

Safety of lercanidipine during pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the Lerakta product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both Lerakta (lercanidipine) and amlodipine belong to the dihydropyridine class of calcium‑channel blockers and lower blood pressure by vasodilation. Lercanidipine is more lipophilic, offering a slower onset and longer vascular residence, which may translate into a smoother blood‑pressure profile for some patients.

Lerakta tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children.

Lerakta is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional.

Serious adverse events, although rare, include severe hypotension, myocardial infarction, and angioedema. Patients should seek immediate medical attention if they experience sudden dizziness, fainting, chest pain, swelling of the face or throat, or difficulty breathing.

Lerakta is contraindicated in patients with severe hypotension, cardiogenic shock, or known hypersensitivity to lercanidipine or any component of the formulation. It should also be used with caution in individuals with significant hepatic impairment.